Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Comparing the biological impact of glatiramer acetate with the biological impact of a generic.
Clinical and MRI characterization of MS patients with a pure and severe cognitive onset.
Positive year one results from Biogen Idec's Phase 3 advance trial of PLEGRIDY™ (peginterferon beta-1a) presented at AAN meeting
Diminished Th17 (not Th1) responses underlie multiple sclerosis disease abrogation after hematopoietic stem cell transplantation.
Food and Drug Administration Approval Letter for Alemtuzumab
Phase 2 BOLD extension study efficacy results for siponimod (BAF312) in patients with relapsing-remitting multiple sclerosis.
Anti-myelin oligodendrocyte glycoprotein antibodies in pediatric patients with optic neuritis.
Antiviral drug ganciclovir is a potent inhibitor of microglial proliferation and neuroinflammation.
Fine-Mapping the Genetic Association of the Major Histocompatibility Complex in Multiple Sclerosis: HLA and Non-HLA Effects.
Axonal conduction and injury in multiple sclerosis: the role of sodium channels.
English Court of Appeal finds in favor of Teva on Copaxone(R) patent litigation and upholds validity of Copaxone patent until May 2015
RGC-32 as a potential biomarker of relapse and response to treatment with glatiramer acetate in multiple sclerosis.
Cross-cultural Adaptation, Reliability, and Validity of the BICAMS in Brazil.
Therapeutic effects of novel sphingosine-1-phosphate receptor agonist W-061 in murine DSS colitis.
Stress signaling etches heritable marks on chromatin.
Tumefactive Demyelinating Lesions in Multiple Sclerosis and Associated Disorders.
The potential role of epigenetic modifications in the heritability of multiple sclerosis.
A pilot trial of low-dose naltrexone in primary progressive multiple sclerosis.
Substance Name: Amiloride
White matter astrocytes in health and disease.
Targeting blood-brain barrier sphingolipid signaling reduces basal P-glycoprotein activity and improves drug delivery to the brain.
Peripheral accumulation of newly produced T and B lymphocytes in natalizumab-treated multiple sclerosis patients.
Motor skill learning requires active central myelination.
Rapid depletion of B lymphocytes by ultra-low-dose rituximab delivered intrathecally.
The therapeutic potential of mesenchymal stem cell transplantation as a treatment for multiple sclerosis: consensus report of the International MSCT Study Group.

Pages